Drug Trial Radar · NCT02260817
Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Dec 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
109
Actual
Start
Oct 2014
Primary completion
Jun 2016
Study completion Jun 2018
Sponsor
- Lead sponsor
- Global Isotopes, LLC d/b/a Zevacor MolecularIndustry
- Sponsor type
- Industry
- First posted
- Oct 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will target approximately 100 men over age 18 who have a biochemical relapse or other evidence of relapse of prostate cancer after primary treatment. The purpose of this study is to: A. Provide expanded access the drug 11C-choline. B. Determine the performance characteristics (sensitivity, specificity, positive predictive value, negative predictive value) of 11C-choline PET/Computed Tomography (CT) and PET/Magnetic Resonance Imaging (MRI) in the detection of metastatic prostate cancer in patients with biochemical relapse of prostate cancer after primary treatment in a prospective manner. C. Determine the optimal Prostate-Specific Antigen (PSA) trigger value in 11C-choline PET/CT and PET/MRI positive patients through a prospective study. D. Determine factors that predict a confirmed positive 11C-choline PET/CT and PET/MRI using a multivariable analysis of clinical and pathologic data collected prospectively. E. Compare the individual performance characteristics of 11C-choline PET/CT and 11C-choline PET/MRI and the combination of 11C-choline PET/CT and PET/MRI Study Protocol: 1. Patients entered into the study will undergo a 11C-choline PET CT scan and MRI scan. 2. The CT and MRI images will be evaluated for evidence of metastatic prostate cancer. 3. The 11C-choline PET CT and MRI images will be evaluated for evidence of metastatic prostate cancer. 4. Evidence of metastasis on conventional imaging or 11C-choline PET will be confirmed with biopsy or surgical pathology when possible, or by response to treatment on subsequent imaging. 5. Rates of confirmed metastasis between conventional CT and MRI images will be compared with the 11C-choline PET CT and MRI images. 6. Upon conclusion of each imaging protocol, the referring physician will receive written documentation of the results. At this time, the patient will be considered off study and no further follow up is required.
Conditions
- Metastatic Prostate Cancer
Interventions
11C-choline InjectionDrug
1. Choline C11 Injection for PET/CT Imaging Protocol: * 15 - millicuries (mCi) 11C-choline IV Injection * PET images skull base to mid thigh with 3 min per bed position * Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol * Fusion of PET and CT images 2. Choline C11 Injection for PET/MRI Whole Body Imaging Protocol: * No IV contrast * High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs * Fusion of coronal and PET images
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evidence of Metastatic Prostate CancerTime frame: After 11C-choline PET CT scan and MRI scans, approximately 1 day. If surgery or response to treatment required to evaluate, approximately 1 to 3 months.
- Sensitivity of 11C Choline PET Imaging ScansTime frame: Approximately 1 day post-scan for patient results
- Specificity of 11C Choline PET Imaging ScansTime frame: Approximately 1 day post-scan for patient results
- Positive Predictive Value (PPV) of 11C Choline PET Imaging ScansTime frame: Approximately 1 day post-scan for patient results
- Negative Predictive Value (NPV) of 11C Choline PET Imaging ScansTime frame: Approximately 1 day post-scan for patient results
- Count of Participants With Positive or Negative PET, CT, or MRI Modalities Resulting in Prostate Cancer (PCa) ConfirmationTime frame: Approximately 1 day post-scan for patient results
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Decatur Memorial Hospital
Decatur, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.